Chandra Vargeese - Wave Life Head of Drug Discovery and Sr. VP
| WVE Stock | USD 15.10 0.11 0.73% |
SVP
Dr. Chandra Vargeese, Ph.D. is the Senior Vice President, Head of Drug Discovery of the company. Dr. Vargeese has served as our Senior Vice President, Head of Drug Discovery since August 2014. Before joining us, Dr. Vargeese served as Novartis Executive Director and Head of RNA Chemistry and Delivery, a position she held from 2008 to 2014. Prior to joining Novartis, Dr. Vargeese led siRNA delivery in the RNA Therapeutics division at Merck Co., where she served as Senior Director and Head of RNA Chemistry and Delivery. Dr. Vargeese joined Merck through its acquisition of Sirna Therapeutics, where she was Vice President of Chemistry. Before Sirna, Dr. Vargeese served as Associate Director of Chemistry at NeXstar Pharmaceuticals and is the coinventor of Macugen, an approved therapy for treating wet AMD since 2014.
| Age | 63 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | Marina One East Tower, Singapore, Singapore, 018936 |
| Phone | 65 6236 3388 |
| Web | https://www.wavelifesciences.com |
Chandra Vargeese Latest Insider Activity
Tracking and analyzing the buying and selling activities of Chandra Vargeese against Wave Life stock is an integral part of due diligence when investing in Wave Life. Chandra Vargeese insider activity provides valuable insight into whether Wave Life is net buyers or sellers over its current business cycle. Note, Wave Life insiders must abide by specific rules, including filing SEC forms every time they buy or sell Wave Life'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Chandra Vargeese over three months ago Acquisition by Chandra Vargeese of 50000 shares of Wave Life at 10.48 subject to Rule 16b-3 | ||
Chandra Vargeese over six months ago Acquisition by Chandra Vargeese of 361700 shares of Wave Life subject to Rule 16b-3 | ||
Chandra Vargeese over a year ago Sale by Chandra Vargeese of 10249 shares of Wave Life |
Wave Life Management Efficiency
The company has Return on Asset of (0.3404) % which means that on every $100 spent on assets, it lost $0.3404. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (2.4382) %, meaning that it generated no profit with money invested by stockholders. Wave Life's management efficiency ratios could be used to measure how well Wave Life manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.22. In addition to that, Return On Capital Employed is expected to decline to -0.81. At present, Wave Life's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 3.33, whereas Other Assets are forecasted to decline to about 4.1 M.Management Performance
| Return On Equity | -2.44 | ||||
| Return On Asset | -0.34 |
Wave Life Sciences Leadership Team
Elected by the shareholders, the Wave Life's board of directors comprises two types of representatives: Wave Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Wave. The board's role is to monitor Wave Life's management team and ensure that shareholders' interests are well served. Wave Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Wave Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kate Rausch, Investor Relations | ||
| Stephen Lake, VP Devel | ||
| Linda JD, Senior Counsel | ||
| Erik MD, Chief Officer | ||
| Sridhar Vaddeboina, Manufacturing Chemistry | ||
| MBA MD, CEO Pres | ||
| HsiuChiung Yang, Senior Medicine | ||
| MD MBA, CEO President | ||
| Daryn Lewis, Senior Resources | ||
| Kyle CFA, CFO Officer | ||
| AnneMarie LiKwaiCheung, Chief Officer | ||
| Chandra Vargeese, Head of Drug Discovery and Sr. VP | ||
| Jonathan Rosin, Chief Officer | ||
| Christopher Francis, Head of Bus. Devel. and VP |
Wave Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Wave Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.44 | ||||
| Return On Asset | -0.34 | ||||
| Profit Margin | (2.66) % | ||||
| Operating Margin | 8.33 % | ||||
| Current Valuation | 2.02 B | ||||
| Shares Outstanding | 152.52 M | ||||
| Shares Owned By Insiders | 15.03 % | ||||
| Shares Owned By Institutions | 78.48 % | ||||
| Number Of Shares Shorted | 6.45 M | ||||
| Price To Earning | (6.50) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Wave Life Sciences is a strong investment it is important to analyze Wave Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Wave Life's future performance. For an informed investment choice regarding Wave Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Wave Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Wave Life. If investors know Wave will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Wave Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 0.427 | Quarterly Revenue Growth (0.11) | Return On Assets (0.34) | Return On Equity (2.44) |
The market value of Wave Life Sciences is measured differently than its book value, which is the value of Wave that is recorded on the company's balance sheet. Investors also form their own opinion of Wave Life's value that differs from its market value or its book value, called intrinsic value, which is Wave Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Wave Life's market value can be influenced by many factors that don't directly affect Wave Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Wave Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Wave Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Wave Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.